Bank of America Corp DE Purchases 9,760 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Bank of America Corp DE raised its position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 37.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,168 shares of the biopharmaceutical company’s stock after acquiring an additional 9,760 shares during the period. Bank of America Corp DE owned approximately 0.11% of Achieve Life Sciences worth $127,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in shares of Achieve Life Sciences by 11.7% during the fourth quarter. Northern Trust Corp now owns 416,796 shares of the biopharmaceutical company’s stock worth $1,467,000 after acquiring an additional 43,682 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Achieve Life Sciences by 185.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 4,905 shares during the period. Barclays PLC boosted its stake in shares of Achieve Life Sciences by 12.2% in the fourth quarter. Barclays PLC now owns 53,473 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 5,818 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Achieve Life Sciences in the fourth quarter valued at approximately $554,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Achieve Life Sciences by 70.6% in the fourth quarter. Renaissance Technologies LLC now owns 61,160 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 25,300 shares during the period. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Trading Down 4.6%

Shares of ACHV stock opened at $3.10 on Tuesday. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The stock has a market cap of $107.52 million, a P/E ratio of -2.74 and a beta of 1.63. The stock has a 50 day simple moving average of $2.82 and a 200 day simple moving average of $3.12. Achieve Life Sciences, Inc. has a 1 year low of $1.84 and a 1 year high of $5.31.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting the consensus estimate of ($0.37). On average, research analysts predict that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.